Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Abrocitinib: First Approval
Emma D. Deeks, Sean T. Duggan
Drugs (2021) Vol. 81, Iss. 18, pp. 2149-2157
Open Access | Times Cited: 91

Showing 1-25 of 91 citing articles:

Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update
Robert Roskoski
Pharmacological Research (2022) Vol. 187, pp. 106552-106552
Open Access | Times Cited: 243
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Xue Chen, Qinfan Yao, Xinyu Gu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 226
A Comprehensive Overview of Globally Approved JAK Inhibitors
Ahmed M. Shawky, Faisal A. Almalki, Ashraf N. Abdalla, et al.
Pharmaceutics (2022) Vol. 14, Iss. 5, pp. 1001-1001
Open Access | Times Cited: 205
CD23 + IgG1 + memory B cells are poised to switch to pathogenic IgE production in food allergy
Miyo Ota, Kenneth B. Hoehn, Weslley Fernandes‐Braga, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 733
Open Access | Times Cited: 41
Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders
Robert Roskoski
Pharmacological Research (2022) Vol. 183, pp. 106362-106362
Closed Access | Times Cited: 64
Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis
Helena Iznardo, Esther Roé, E. Serra‐Baldrich, et al.
Pharmaceutics (2023) Vol. 15, Iss. 2, pp. 385-385
Open Access | Times Cited: 23
Therapeutic Targeting of the Janus Kinase/Signal Transducer and Activator of Transcription Pathway in Cutaneous T-Cell Lymphoma
Alisha Kashyap, Julia Dai, Xiao Ni
Cancers (2025) Vol. 17, Iss. 4, pp. 568-568
Open Access | Times Cited: 1
Successful Treatment of Delayed Onset Nodules After Dermal Fillers Injection with Abrocitinib: A Case Report
Zhen Li, Jiejie Lu, Miaoting Wu, et al.
Clinical Cosmetic and Investigational Dermatology (2025) Vol. Volume 18, pp. 955-959
Open Access | Times Cited: 1
New drug approvals for 2022: Synthesis and clinical applications
Shuo Yuan, Dandan Shen, Rui Jia, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 6, pp. 2352-2391
Closed Access | Times Cited: 18
SOCS-JAK-STAT inhibitors and SOCS mimetics as treatment options for autoimmune uveitis, psoriasis, lupus, and autoimmune encephalitis
Rahul Pandey, Marina Bakay, Hákon Hákonarson
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 18
Potential applications of JAK inhibitors, clinically approved drugs against autoimmune diseases, in cancer therapy
Xiaohuan Wei, Yuanyuan Liu
Frontiers in Pharmacology (2024) Vol. 14
Open Access | Times Cited: 7
Visible-Light-Induced Highly Site-Selective Direct C–H Phosphorylation of Pyrrolo[2,3-d]pyrimidine Derivatives with H-Phosphine Oxides
Zhuo Zhang, Mingrui Liu, Min Liu, et al.
The Journal of Organic Chemistry (2024) Vol. 89, Iss. 5, pp. 2996-3009
Closed Access | Times Cited: 7
A comprehensive review of small molecule drugs approved by the FDA in 2023: Advances and prospects
Yi‐Ru Bai, Dong‐Jie Seng, Ying Xu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 276, pp. 116706-116706
Closed Access | Times Cited: 7
Applications of Isosteres of Piperazine in the Design of Biologically Active Compounds: Part 2
Nicholas A. Meanwell, Olivier Loiseleur
Journal of Agricultural and Food Chemistry (2022) Vol. 70, Iss. 36, pp. 10972-11004
Closed Access | Times Cited: 27
Successful treatment of alopecia universalis with abrocitinib: a case report
J. Zhang, Ya‐Gang Zuo
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 16
Synthetic Approaches to the New Drugs Approved During 2021
Emma L. McInturff, Scott P. France, Carolyn A. Leverett, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 15, pp. 10150-10201
Closed Access | Times Cited: 15
Improvement of Hailey–Hailey disease with abrocitinib
Yufen Li, Yiqun Jiang, Jianfang Sun
Clinical and Experimental Dermatology (2023) Vol. 48, Iss. 5, pp. 532-533
Open Access | Times Cited: 14
Synthesis of organic solvent‐free nitrogen‐doped carbon quantum dots as unique green fluorimetric probes for analysis of abrocitinib in human plasma
Baher I. Salman, Mohamed A. Abdel‐Lateef, Eman Alzahrani, et al.
Luminescence (2024) Vol. 39, Iss. 6
Open Access | Times Cited: 6
The memory of pathogenic IgE is contained within CD23+IgG1+memory B cells poised to switch to IgE in food allergy
Miyo Ota, Kenneth B. Hoehn, Takayuki Ota, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 11
Synthesis, in silico modelling, and in vitro biological evaluation of substituted pyrazole derivatives as potential anti-skin cancer, anti-tyrosinase, and antioxidant agents
Samuel Boateng, Tithi Roy, Kara Torrey, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2023) Vol. 38, Iss. 1
Open Access | Times Cited: 11
Biologics and Small Molecule Targeted Therapies for Pediatric Alopecia Areata, Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa in the US: A Narrative Review
Robin C. Yi, Shannon Moran, Hannah Y. Gantz, et al.
Children (2024) Vol. 11, Iss. 8, pp. 892-892
Open Access | Times Cited: 4
Efficacy and safety of Janus kinase inhibitors in the treatment of psoriasis and psoriatic arthritis: An analysis of evidence from 2014 to 2022
Jiao Wang, Tian Ma, Xiaoying Sun, et al.
Heliyon (2025), pp. e42084-e42084
Open Access
Abrocitinib in the Treatment of Drug Reaction With Eosinophilia and Systemic Symptoms
ZhiQin Zhang, Juan Liu, Di Wu, et al.
American Journal of Therapeutics (2025)
Closed Access
A pharmacovigilance analysis of abrocitinib-related skin adverse events based on the FDA Adverse Event Reporting System (FAERS)
Min Huang, Peng Li
Archives of Dermatological Research (2025) Vol. 317, Iss. 1
Closed Access
Abrocitinib Treatment for Localized Type of Generalized Pustular Psoriasis: A Case Report
Zhonghua Yang, Jiejie Lu, Zhen Li
Clinical Cosmetic and Investigational Dermatology (2025) Vol. Volume 18, pp. 663-668
Open Access
Page 1 - Next Page

Scroll to top